MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Protagonist Therapeutics Inc

Closed

SectorHealthcare

44.84 -2.9

Overview

Share price change

24h

Current

Min

44.19

Max

45.93

Key metrics

By Trading Economics

Income

165M

132M

Sales

166M

171M

P/E

Sector Avg

10.827

57.333

EPS

1.98

Profit margin

77.166

Employees

126

EBITDA

168M

127M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+51.17% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

631M

2.8B

Previous open

47.74

Previous close

44.84

Technical Score

By Trading Central

Confidence

Bullish Evidence

Protagonist Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Mar 2025, 13:59 UTC

Major Market Movers

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Peer Comparison

Price change

Protagonist Therapeutics Inc Forecast

Price Target

By TipRanks

51.17% upside

12 Months Forecast

Average 67.8 USD  51.17%

High 82 USD

Low 38 USD

Based on 10 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

42.62 / 45.85Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.